{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:09:43Z","timestamp":1790424583818,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41409-025-02667-2","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:23:26Z","timestamp":1752679406000},"page":"1325-1332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4827-4401","authenticated-orcid":false,"given":"Sebastian","family":"Giebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-4748","authenticated-orcid":false,"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-3919","authenticated-orcid":false,"given":"Ryszard","family":"Swoboda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kottaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Gabellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-0227","authenticated-orcid":false,"given":"Xavier","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Nur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Pinho","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2667_CR1","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396\u2013407.","journal-title":"Blood"},{"key":"2667_CR2","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109:1408\u201313.","journal-title":"Blood"},{"key":"2667_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","volume":"108","author":"B Wassmann","year":"2006","unstructured":"Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469\u201377.","journal-title":"Blood"},{"key":"2667_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","volume":"143","author":"M Yanada","year":"2008","unstructured":"Yanada M, Sugiura I, Takeuchi J, Akiyama H, Usui N, Yagasaki F, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol. 2008;143:503\u201310.","journal-title":"Br J Haematol"},{"key":"2667_CR5","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","volume":"125","author":"Y Chalandon","year":"2015","unstructured":"Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711\u20139.","journal-title":"Blood"},{"key":"2667_CR6","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Fo\u00e0","year":"2011","unstructured":"Fo\u00e0 R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521\u20138.","journal-title":"Blood"},{"key":"2667_CR7","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024;331:1814\u201323.","journal-title":"JAMA"},{"key":"2667_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","volume":"7","author":"AS Advani","year":"2023","unstructured":"Advani AS, Moseley A, O\u2019Dwyer KM, Wood BL, Park J, Wieduwilt M, et al. Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023;7:1279\u201385.","journal-title":"Blood Adv"},{"key":"2667_CR9","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Fo\u00e0","year":"2020","unstructured":"Fo\u00e0 R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020;383:1613\u201323.","journal-title":"N Engl J Med"},{"key":"2667_CR10","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e24\u2013e34.","journal-title":"Lancet Haematol"},{"key":"2667_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1200\/JCO.23.01075","volume":"42","author":"R Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol. 2024;42:881\u20135.","journal-title":"J Clin Oncol"},{"key":"2667_CR12","doi-asserted-by":"publisher","first-page":"112972","DOI":"10.18632\/oncotarget.22934","volume":"8","author":"G Roth-Guepin","year":"2017","unstructured":"Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget. 2017;8:112972\u20139.","journal-title":"Oncotarget"},{"key":"2667_CR13","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymph oblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941\u201351.","journal-title":"Cancer"},{"key":"2667_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"S Giebel","year":"2019","unstructured":"Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 2019;54:798\u2013809.","journal-title":"Bone Marrow Transpl"},{"key":"2667_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695\u2013706.","journal-title":"Stat Med"},{"key":"2667_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"2667_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00985760","volume":"1","author":"P Hoogard","year":"1995","unstructured":"Hoogard P. Frailty model for survival data. Lifetime Data Anal. 1995;1:255\u201373.","journal-title":"Lifetime Data Anal"},{"key":"2667_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u20131500.","journal-title":"Stat Med"},{"key":"2667_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41409-020-01005-y","volume":"56","author":"A Nagler","year":"2021","unstructured":"Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2021;56:218\u201324.","journal-title":"Bone Marrow Transpl"},{"key":"2667_CR20","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676\u20138.","journal-title":"Blood"},{"key":"2667_CR21","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot P, Coud\u00e9 MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016;128:774\u201382.","journal-title":"Blood"},{"key":"2667_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2018-99-114552","volume":"132","author":"OG Ottmann","year":"2018","unstructured":"Ottmann OG, Pfeifer H, Cayuela J-M, Spiekermann K, Jung W, Beck J, et al. Nilotinib (Tasigna\u00ae) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). Blood. 2018;132:31.","journal-title":"Blood"},{"key":"2667_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.clml.2023.01.002","volume":"23","author":"M Shahzad","year":"2023","unstructured":"Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, et al. Outcomes of tyrosine kinase inhibitors maintenance therapy with or without allogeneic hematopoietic stem cell transplantation in philadelphia chromosome positive acute lymphoblastic leukemia in first complete remission: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2023;23:178\u201387.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2667_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammedet KA, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022;140:2101\u201312.","journal-title":"Blood"},{"key":"2667_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.27237","volume":"99","author":"S Nishiwaki","year":"2024","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. Utility of allogeneic stem cell transplantation for adult Ph+ ALL with complete molecular remission. Am J Hematol. 2024;99:806\u201315.","journal-title":"Am J Hematol"},{"key":"2667_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","volume":"12","author":"J Pavl\u016f","year":"2019","unstructured":"Pavl\u016f J, Labopin M, Niittyvuopio R, Soci\u00e9 G, Yakoub-Agha I, Wu D, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019;12:108.","journal-title":"J Hematol Oncol"},{"key":"2667_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejca.2018.11.003","volume":"106","author":"S Giebel","year":"2019","unstructured":"Giebel S, Labopin M, Czerw T, Soci\u00e9 G, Blaise D, Ghavamzadeh A, et al. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019;106:212\u20139.","journal-title":"Eur J Cancer"},{"key":"2667_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2018.03.018","volume":"96","author":"S Giebel","year":"2018","unstructured":"Giebel S, Labopin M, Potter M, Poir\u00e9 X, Sengeloev H, Soci\u00e9 G, et al. Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2018;96:73\u201381.","journal-title":"Eur J Cancer"},{"key":"2667_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","volume":"34","author":"N Shem-Tov","year":"2020","unstructured":"Shem-Tov N, Peczynski C, Labopin M, It\u00e4l\u00e4-Remes M, Blaise D, Labussi\u00e8re-Wallet H, et al. Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. Leukemia. 2020;34:283\u201392.","journal-title":"Leukemia"},{"key":"2667_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-021-01065-7","volume":"14","author":"A Nagler","year":"2021","unstructured":"Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol. 2021;14:53.","journal-title":"J Hematol Oncol"},{"key":"2667_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-021-01094-2","volume":"14","author":"J Sanz","year":"2021","unstructured":"Sanz J, Galimard JE, Labopin M, Afanasyev B, Sergeevich MI, Angelucci E, et al. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol. 2021;14:84.","journal-title":"J Hematol Oncol"},{"key":"2667_CR32","first-page":"182.e1","volume":"29","author":"JA Webster","year":"2023","unstructured":"Webster JA, Reed M, Tsai HL, Ambinder A, Jain T, Dezern AE, et al. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age 55 Years. Transpl Cell Ther. 2023;29:182.e1\u2013182.e8.","journal-title":"Transpl Cell Ther"},{"key":"2667_CR33","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1002\/cncr.35004","volume":"129","author":"S Giebel","year":"2023","unstructured":"Giebel S, Labopin M, Salmenniemi U, Soci\u00e9 G, Bondarenko S, Blaise D, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2023;129:3735\u201345.","journal-title":"Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02667-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02667-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:11:44Z","timestamp":1761847904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02667-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02667-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}